AASLD 2015: Gilead Leads Race To Shorter, Pan-Genotypic HCV Treatments
This article was originally published in Scrip
Executive Summary
Gilead Sciences has led the race to market with ribavirin- and interferon-free therapies that cure most people with the hepatitis C virus (HCV), but Merck & Co. Inc. is gaining ground in the sprint toward shorter-term, pan-genotypic, two- and three-drug regimens, with AbbVie Inc. on their heels with its own dual therapy that also may eliminate HCV infection in some of the most difficult to treat patients.
You may also be interested in...
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.